In multiple myeloma, CTLA-4 inhibitors enhance effector T cell function by blocking early T cell activation signals, but this is associated with severe immune-related toxicities (such as colitis and hepatitis). This evidence concerns the gene CTLA4 and plasma cell myeloma.